Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2004 for prevention of venous thromboembolism after elective total knee arthroplasty
CTR20250464Phase 3Completed
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-2004 in venous thromboembolism (VTE), sponsored by Beijing Shengdi Pharmaceutical. Started Feb 2025; status: completed.
02
Drugs
SHR-2004
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on CTR20250464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250464.